List of Excipients in Branded Drug NADOLOL AND BENDROFLUMETHIAZIDE

« Back to Dashboard

Generic Drugs Containing NADOLOL AND BENDROFLUMETHIAZIDE

Company	Ingredient	NDC	Excipient
Impax Generics	nadolol and bendroflumethiazide	0115-5311	CELLULOSE, MICROCRYSTALLINE
Impax Generics	nadolol and bendroflumethiazide	0115-5311	CROSCARMELLOSE SODIUM
Impax Generics	nadolol and bendroflumethiazide	0115-5311	HYPROMELLOSES
Impax Generics	nadolol and bendroflumethiazide	0115-5311	LACTOSE MONOHYDRATE
Impax Generics	nadolol and bendroflumethiazide	0115-5311	MAGNESIUM STEARATE
Impax Generics	nadolol and bendroflumethiazide	0115-5311	MANNITOL

What are the Most Frequently-Used Excipients in NADOLOL AND BENDROFLUMETHIAZIDE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	HYPROMELLOSES
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	MANNITOL

Nadolol and Bendroflumethiazide Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Nadolol/bendroflumethiazide is a legacy fixed-dose antihypertensive combination with limited current commercial visibility but a technically manageable reformulation opportunity. The principal opportunity is a low-cost, multi-strength generic or authorized-generic product using conventional direct-compression excipients, improved tablet manufacturability, and differentiated packaging or supply reliability. The combination is not a biologic and does not present biosimilar competition.

What is the nadolol and bendroflumethiazide combination?

Nadolol/bendroflumethiazide combines a nonselective beta-adrenergic blocker with a thiazide diuretic. The historical U.S. reference product is Corzide, indicated for hypertension in patients requiring combined beta-blocker and diuretic therapy.[1]

Attribute	Nadolol/bendroflumethiazide
Therapeutic class	Beta-blocker/thiazide diuretic
Active ingredients	Nadolol and bendroflumethiazide
Historical brand	Corzide
U.S. dosage strengths	40/5 mg, 80/5 mg, 80/10 mg, 160/5 mg and 160/10 mg
Dosage form	Immediate-release tablet
Primary indication	Hypertension
Regulatory pathway	NDA reference product and generic ANDA pathway
Biosimilar exposure	None
Main commercial issue	Small, mature market with limited brand support

The combination reduces pill burden but has a restricted modern market because clinicians can separately titrate beta-blocker and diuretic doses. Fixed-dose therapy also faces competition from newer antihypertensive combinations involving renin-angiotensin system blockers, calcium-channel blockers and thiazide-type diuretics.

What formulations are protected by the original product?

The historical product is an immediate-release tablet rather than an extended-release, enteric-coated or modified-release system. The formulation challenge is therefore manufacturing consistency rather than sophisticated drug delivery.

Public product information identifies conventional tablet excipients, including fillers, binders, disintegrants, lubricants and coloring materials. Exact excipient composition can vary by strength and manufacturer. A generic developer should treat the reference formulation as a performance target, not necessarily as the optimal commercial formulation.[1]

Key formulation characteristics

Nadolol has low aqueous solubility and can create blend-uniformity and dissolution concerns at higher drug loads. Bendroflumethiazide is present at a much lower dose, particularly in the 5 mg strengths. The formulation must therefore control low-dose content uniformity while accommodating the much larger nadolol mass.

The core technical risks are:

• Segregation of bendroflumethiazide during blending and compression.
• Variable wetting and dissolution caused by hydrophobic lubricants.
• Tablet weight and hardness differences across the 40 mg, 80 mg and 160 mg nadolol strengths.
• Stability of low-dose bendroflumethiazide under heat and humidity.
• Visual differentiation of multiple strengths.
• Dissolution comparability to the reference product.

Which excipient strategy is most commercially attractive?

A direct-compression formulation is the most commercially attractive starting point where powder flow, compressibility and low-dose uniformity are adequate. It minimizes processing steps and supports a common manufacturing platform across strengths.

Recommended excipient architecture

Formulation function	Candidate excipient classes	Commercial rationale
Primary diluent	Microcrystalline cellulose, lactose monohydrate, dibasic calcium phosphate	Supports tablet mass and compression
Secondary diluent	Spray-dried lactose or mannitol	Improves flow and mouthfeel where needed
Binder	Copovidone or low-substituted hydroxypropyl cellulose	Supports mechanical strength without excessive granule hardness
Disintegrant	Crospovidone, croscarmellose sodium or sodium starch glycolate	Promotes immediate release
Lubricant	Magnesium stearate, sodium stearyl fumarate	Controls ejection and sticking
Glidant	Colloidal silicon dioxide	Improves flow and blend uniformity
Colorant	Approved iron oxides or other permitted colorants	Enables strength differentiation
Film coat	Hypromellose-based coating	Improves handling, identification and patient acceptability

A lactose/microcrystalline-cellulose platform is likely to offer the best balance of cost and manufacturability. A calcium-phosphate platform may improve hardness and reduce tablet size, but it can alter disintegration and dissolution. Mannitol is commercially useful for a premium, low-lactose or improved-mouthfeel version, although the market may not support the additional cost.

Low-dose blend strategy

The 5 mg bendroflumethiazide dose creates the central content-uniformity problem. A geometric dilution process is necessary if the active ingredients are blended directly. A more robust approach is ordered premixing or granulation of bendroflumethiazide with a small quantity of carrier before final blending with nadolol and the remaining excipients.

Potential strategies include:

1. Ordered mixing: Preblend bendroflumethiazide with a fine-particle diluent, then add the premix to the nadolol blend.
2. Wet granulation: Granulate the low-dose component with a binder to reduce segregation, followed by addition of nadolol and external phase excipients.
3. Dry granulation: Use roller compaction where moisture sensitivity or process simplicity favors a dry process.
4. Separate granulation: Prepare a bendroflumethiazide-containing granule and combine it with nadolol before compression.

Direct compression is commercially preferable, but separate or wet granulation may reduce validation risk for the 5 mg strengths. The final choice should be driven by blend-uniformity data, not by excipient cost alone.

How should a generic manufacturer design the strength portfolio?

A manufacturer should build one formulation platform covering the five historical strengths, with controlled changes in tablet weight, active ratio, color and tooling.

Strength	Nadolol	Bendroflumethiazide	Development priority
40/5 mg	40 mg	5 mg	Entry strength and low-dose uniformity
80/5 mg	80 mg	5 mg	High nadolol-to-diuretic ratio
80/10 mg	80 mg	10 mg	Higher diuretic load
160/5 mg	160 mg	5 mg	Largest nadolol load with low-dose challenge
160/10 mg	160 mg	10 mg	Highest total drug load

The 160/5 mg tablet is likely to be the most technically demanding because it combines the largest nadolol load with the lowest bendroflumethiazide proportion. A common blend may not work equally well across all strengths. A bracketing or matrix approach can reduce development work, but the sponsor must demonstrate that the selected strengths represent the relevant formulation risks.

What FDA regulatory requirements apply?

A generic product would generally proceed under an abbreviated new drug application if the reference product and applicable FDA product-specific guidance support that pathway.[2] The developer must establish pharmaceutical equivalence, bioequivalence, manufacturing quality and labeling conformity.

Regulatory priorities

The major regulatory workstreams are:

• Identification of the correct reference listed drug.
• Confirmation of the active-ingredient and strength nomenclature.
• Comparative dissolution testing for all strengths.
• In vitro release testing appropriate for an immediate-release tablet.
• Assay and content-uniformity validation for bendroflumethiazide.
• Impurity and degradation-product control for both active ingredients.
• Stability data under ICH conditions.
• Demonstration of acceptable tablet hardness, friability and disintegration.
• Labeling that matches the reference product unless a permitted difference applies.

Because nadolol is systemically active and bendroflumethiazide affects fluid and electrolyte balance, product quality failures could create clinically material risks. The label identifies contraindications and warnings relating to bronchospastic disease, cardiac conduction abnormalities, renal impairment, electrolyte disturbances and abrupt beta-blocker withdrawal.[1]

What is the Orange Book status of nadolol and bendroflumethiazide?

The commercial product should be evaluated through the FDA Orange Book and current FDA Drugs@FDA records before filing. Historical Corzide approval information is associated with an NDA for the combination product, while generic entry depends on the current reference-listed-drug status and any active exclusivity or patent certifications.

No biosimilar pathway applies because the product is a small-molecule tablet. Patent certification, if required, would be handled through the ANDA process under the applicable Orange Book listing and statutory certification framework.[2]

Exclusivity and patent position

Nadolol and bendroflumethiazide are mature active ingredients. The principal composition-of-matter and early formulation patent periods associated with the legacy product would ordinarily have expired long ago. Commercial protection is therefore more likely to depend on:

• Current Orange Book listings, if any remain.
• Product-specific regulatory exclusivity.
• Formulation or process patents, if listed and still enforceable.
• Manufacturing economics and supply reliability.
• State substitution and formulary positioning.
• Any settlement or licensing arrangements associated with an ANDA.

A filing decision should not assume that historical brand patents create a present barrier. The relevant question is whether an unexpired, listed patent blocks approval or launch at the time of the proposed ANDA.

When does nadolol/bendroflumethiazide lose exclusivity?

The original exclusivity period has long expired in commercial terms. The combination is a legacy product, and the principal commercial opportunity is generic substitution rather than post-exclusivity lifecycle management by the originator.

Exact patent expiration dates should be confirmed from the FDA Orange Book and USPTO records for the relevant NDA and listed patents. No current commercial strategy should rely on unverified historical patent dates, particularly where the branded product may have changed ownership, been discontinued, or had its listing status revised.

Are there Paragraph IV challenges or patent litigation risks?

The product class presents lower patent litigation risk than recently launched small molecules because the active ingredients and dosage form are old. A Paragraph IV risk assessment remains necessary if any live patents are listed against the reference product.

Litigation exposure

A potential ANDA sponsor should review:

• Orange Book patent listings for the reference NDA.
• FDA patent-certification requirements.
• Federal district court complaints filed after notice of a Paragraph IV certification.
• Any 30-month stay triggered by timely patent litigation.
• Settlement terms that restrict launch timing.
• Whether patents cover the combination, a formulation, a method of use or a manufacturing process.

No reliable commercial conclusion should be drawn from the existence of historical litigation involving nadolol alone or bendroflumethiazide alone. The relevant risk is product-specific and depends on the proposed labeling and formulation.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are moderate rather than high. The actives are established, the dosage form is conventional, and there is no complex device or sterile process. The main barrier is achieving reproducible low-dose distribution at a cost consistent with a small market.

Manufacturing risks

• Limited supplier base for pharmaceutical-grade bendroflumethiazide.
• API particle-size variability.
• Low-dose segregation during scale-up.
• Compression defects at high nadolol loading.
• Dissolution drift after lubricant-level changes.
• Separate stability behavior of the two actives.
• Need for reliable color and imprint controls across five strengths.

Intellectual-property opportunities

New intellectual-property protection would be more credible around a specific technical improvement than around the old combination itself. Potential areas include:

• A validated low-dose premix that reduces content variability.
• A novel excipient ratio producing a defined dissolution profile.
• A taste-masked or orally disintegrating dosage form.
• A divisible tablet architecture supporting dose titration.
• A moisture-protective coating system.
• A manufacturing process with improved blend uniformity.
• A unit-dose package extending stability in high-humidity markets.

Patentability would depend on novelty, nonobviousness and demonstrable technical benefit. A routine substitution of one standard excipient for another would generally provide weak protection.

What commercial opportunities exist for the combination?

The opportunity is niche but may be attractive for a manufacturer with an existing cardiovascular generic portfolio, established API procurement and efficient low-volume production.

Generic opportunity

A generic launch could target:

• Pharmacies seeking a second-source supplier.
• Long-term-care and institutional channels.
• Wholesalers requiring a legacy product replacement.
• Markets where fixed-dose beta-blocker/thiazide therapy remains established.
• Export jurisdictions with limited access to newer antihypertensive combinations.
• Contract-manufacturing customers that need an unbranded or private-label product.

A five-strength portfolio creates catalog value but also increases inventory complexity. A staged launch could begin with the most commercially relevant strengths and add the remaining products after demand is established, subject to regulatory requirements and market economics.

Reformulation opportunity

A differentiated product could use:

• A smaller tablet.
• Better tablet color coding.
• A score line for dose flexibility.
• A lactose-free formulation.
• A low-dust manufacturing process.
• High-barrier blister packaging.
• Calendar or adherence packaging.
• A supply-stable product positioned for institutional buyers.

These features are unlikely to support a large premium in a conventional generic market. Their value is greatest when they reduce manufacturing cost, improve supply continuity or help win formulary contracts.

How does nadolol/bendroflumethiazide compare with competing antihypertensive combinations?

Product category	Clinical flexibility	Generic competition	Commercial outlook
Nadolol/bendroflumethiazide	Low to moderate because both actives are fixed	Mature	Niche legacy opportunity
Beta-blocker plus hydrochlorothiazide	Similar fixed-dose limitations	Broad	More established generic demand
ACE inhibitor/thiazide	Higher contemporary use in many markets	Broad	Stronger volume potential
ARB/thiazide	Broad use and flexible prescribing	Broad	Larger commercial market
Calcium-channel blocker/thiazide	Less common as a fixed combination	Moderate	Selective opportunity
Separate nadolol plus diuretic	Maximum titration flexibility	Depends on product availability	Competes directly with fixed-dose product

The combination’s main disadvantage is therapeutic flexibility. Its main advantage is a simple, familiar, low-cost tablet for patients already stabilized on both components.

What revenue exposure and launch scenarios are realistic?

The product should be treated as a small-market opportunity unless the sponsor has verified current prescription volume, reimbursement data and reference-product shortages.

Launch scenarios

Base case: A low-cost generic enters a mature, low-volume market with modest share and limited pricing power.

Upside case: A shortage, discontinuation or supplier exit creates a temporary opening for a reliable second source.

Premium case: A manufacturer obtains institutional contracts by offering all strengths, stable supply and improved packaging.

Downside case: Market demand is too low to support five strengths, API procurement is inefficient, or separate generic components displace the fixed-dose product.

The most defensible investment thesis is operational rather than patent-driven: low technical complexity, manageable regulatory requirements and possible value from supply reliability.

Key Takeaways

• Nadolol/bendroflumethiazide is a mature immediate-release antihypertensive combination associated historically with Corzide.
• The strongest formulation issue is low-dose bendroflumethiazide uniformity, especially in the 160/5 mg strength.
• Direct compression is the preferred starting platform, with ordered mixing or granulation available to control segregation.
• Conventional excipients such as microcrystalline cellulose, lactose, crospovidone, colloidal silicon dioxide and magnesium stearate are commercially suitable candidates.
• The product has no biosimilar risk and likely limited residual patent barriers, but current Orange Book records must control the ANDA strategy.
• Commercial value is most likely in generic supply, institutional contracting, export markets and shortage replacement.
• New patent value would require a demonstrable formulation or manufacturing improvement rather than a routine excipient substitution.
• The opportunity is better suited to an established generic manufacturer than to a standalone development program.

FAQs

Is nadolol/bendroflumethiazide still commercially available?

Availability depends on jurisdiction, manufacturer and current FDA listing status. The historical branded product is a legacy product, and market access should be assessed through current FDA and commercial distribution records.

Can nadolol and bendroflumethiazide be developed as an immediate-release generic tablet?

Yes. The historical dosage form is an immediate-release tablet, making an ANDA-oriented formulation strategy technically feasible if the sponsor satisfies reference-product, bioequivalence and quality requirements.

Which strength presents the greatest formulation risk?

The 160/5 mg strength is the most challenging because it combines the highest nadolol load with the lowest bendroflumethiazide proportion, increasing the risk of blend-uniformity failure.

Could a lactose-free formulation create meaningful differentiation?

It could support patient, institutional or export-market positioning, but it would not necessarily justify a substantial price premium. Its commercial value would depend on verified demand and reimbursement conditions.

Is a new patent likely for a standard excipient reformulation?

A routine substitution of common tablet excipients is unlikely to provide strong patent protection. A stronger case would require unexpected performance, improved content uniformity, enhanced stability or a clearly defined manufacturing advantage.

References

1. U.S. Food and Drug Administration. (n.d.). Corzide (nadolol and bendroflumethiazide) prescribing information. Drugs@FDA.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
3. U.S. Food and Drug Administration. (2019). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.
4. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.
5. U.S. Food and Drug Administration. (2022). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.